{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:29:20Z","timestamp":1790058560236,"version":"4.0.1"},"reference-count":179,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.578314","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T16:13:12Z","timestamp":1602259992000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":86,"title":["New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions"],"prefix":"10.3389","volume":"11","author":[{"given":"Nathaniel Edward Bennett","family":"Saidu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Bonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Grce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit","family":"Inngjerdingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Koehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Toubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15719","article-title":"Developing role of B cells in the pathogenesis and treatment of chronic GVHD","volume":"184","author":"Li","year":"2019","journal-title":"Br J Haematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11483","article-title":"Acute Graft Versus Host Disease: A Comprehensive Review","volume":"37","author":"Nassereddine","year":"2017","journal-title":"Anticancer Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2016-06-686618","article-title":"Chronic graft-versus-host disease: biological insights from preclinical and clinical studies","volume":"129","author":"MacDonald","year":"2017","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.12.035","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: preface to the series","volume":"21","author":"Pavletic","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-015-1782-4","article-title":"Therapeutic benefits targeting B-cells in chronic graft-versus-host disease","volume":"101","author":"Nakasone","year":"2015","journal-title":"Int J Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.5500\/wjt.v6.i4.608","article-title":"Biology of chronic graft-vs-host disease: Immune mechanisms and progress in biomarker discovery","volume":"6","author":"Presland","year":"2016","journal-title":"World J Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI75935","article-title":"CSF-1\u2013dependant donor-derived macrophages mediate chronic graft-versus-host disease","volume":"124","author":"Alexander","year":"2014","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201847684","article-title":"GM-CSF therapy inhibits chronic graft-versus-host disease via expansion of regulatory T cells","volume":"49","author":"Hotta","year":"2019","journal-title":"Eur J Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat8410","article-title":"Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF-licensed myeloid cells","volume":"10","author":"Tugues","year":"2018","journal-title":"Sci Transl Med"},{"key":"B11","unstructured":"American Society for Transplantation and Cellular Therapy2019 Beyond Fundamentals of HCT"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2009.0401","article-title":"Myofibroblasts generated in culture from sclerotic skin lesions of a patient with extensive chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation are of recipient origin","volume":"19","author":"Goussetis","year":"2010","journal-title":"Stem Cells Dev"},{"key":"B13","first-page":"296","article-title":"Immunohistologic and ultrastructural study of the sclerotic skin in chronic graft-versus-host disease in man","volume":"115","author":"Janin-Mercier","year":"1984","journal-title":"Am J Pathol"},{"key":"B14","article-title":"A significant role of stromal fibroblasts in rapidly progressive dry eye in patients with chronic GVHD","volume":"42","author":"Ogawa","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.07.040","article-title":"The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index","volume":"25","author":"Pidala","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.254","article-title":"Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity","volume":"26","author":"Grkovic","year":"2012","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113658","article-title":"Microbiota Phylogenic Analysis Revealed Decreased Abundance of Faecalibacterium Prausnitzii, an Anti-Inflammatory Commensal Bacterium, in Patients with Chronic Graft-Versus-Host Disease","volume":"132","author":"Farhadfar","year":"2018","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2018.04.034","article-title":"The Association of Performance Status and Disease Severity in Patients With Chronic Graft-vs-Host Disease","volume":"100","author":"Andrews","year":"2019","journal-title":"Arch Phys Med Rehabil"},{"key":"B19","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/s41409-018-0365-4","article-title":"Negative impact of chronic graft-versus-host disease and glucocorticoid on the recovery of physical function after allogeneic hematopoietic stem cell transplantation","volume":"54","author":"Hayakawa","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017013052","article-title":"Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants","volume":"2","author":"Kumar","year":"2018","journal-title":"Blood Adv"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2603","article-title":"Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants","volume":"103","author":"Randolph","year":"2004","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbmt.2010.05.011","article-title":"Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease","volume":"17","author":"Wolff","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2011.0732","article-title":"The treatment of chronic graft-versus-host disease: consensus recommendations of experts from Germany, Austria, and Switzerland","volume":"108","author":"Wolff","year":"2011","journal-title":"Dtsch Arztebl Int"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-551994","article-title":"How we treat chronic graft-versus-host disease","volume":"125","author":"Flowers","year":"2015","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1365-2141.2012.09128.x","article-title":"Diagnosis and management of chronic graft-versus-host disease","volume":"158","author":"Dignan","year":"2012","journal-title":"Br J Haematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-640672","article-title":"Syk and tired of current chronic GVHD therapies","volume":"125","author":"Fowler","year":"2015","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.04.006","article-title":"Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation","volume":"14","author":"Hamadani","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0855-z","article-title":"Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody\u2014Begelomab","volume":"55","author":"Bacigalupo","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.01.014","article-title":"Nilotinib Treatment of Patients Affected by Chronic Graft-versus-Host Disease Reduces Collagen Production and Skin Fibrosis by Downmodulating the TGF-\u03b2 and p-SMAD Pathway","volume":"26","author":"Marinelli Busilacchi","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI90593","article-title":"Cytokine mediators of chronic graft-versus-host disease","volume":"127","author":"MacDonald","year":"2017","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/2040620717741860","article-title":"New and emerging therapies for acute and chronic graft versus host disease","volume":"9","author":"Hill","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-686659","article-title":"Mechanistic approaches for the prevention and treatment of chronic GVHD","volume":"129","author":"Cutler","year":"2017","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-782466","article-title":"An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD","volume":"130","author":"Poe","year":"2017","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-784017","article-title":"Blazar BR. B-cell targeting in chronic graft-versus-host disease","volume":"131","author":"Zeiser","year":"2018","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-562231","article-title":"Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans","volume":"123","author":"Flynn","year":"2014","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2014.02.008","article-title":"Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease","volume":"74","author":"Le Huu","year":"2014","journal-title":"J Dermatol Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI75328","article-title":"Ibrutinib treatment ameliorates murine chronic graft-versus-host disease","volume":"124","author":"Dubovsky","year":"2014","journal-title":"J Clin Invest"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200677","article-title":"Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease","volume":"189","author":"Young","year":"2012","journal-title":"J Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.92111","article-title":"An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition","volume":"2","author":"Forcade","year":"2017","journal-title":"JCI Insight"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-533562","article-title":"Increased BCR responsiveness in B cells from patients with chronic GVHD","volume":"123","author":"Allen","year":"2014","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-595470","article-title":"Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease","volume":"125","author":"Flynn","year":"2015","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-204669","article-title":"Acute graft-versus-host disease: from the bench to the bedside","volume":"114","author":"Soci\u00e9","year":"2009","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1182\/blood-2005-09-3623","article-title":"Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations","volume":"107","author":"Zhang","year":"2006","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1257","article-title":"Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease","volume":"106","author":"Zorn","year":"2005","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"179ra43","DOI":"10.1126\/scitranslmed.3005265","article-title":"Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease","volume":"5","author":"Matsuoka","year":"2013","journal-title":"Sci Transl Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-114556","article-title":"Artesunate Attenuate Chronic Graft-Versus-Host Disease By Regulating Th17\/Treg Balance","volume":"132","author":"Xiaomei","year":"2018","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-678706","article-title":"Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism","volume":"127","author":"Flynn","year":"2016","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-118098","article-title":"Pre-Clinical Trial to Evaluate the Efficacy of Delayed Administration of Ixazomib in the Prophylaxis of Chronic Graft-Versus-Host Disease","volume":"132","author":"Ramos","year":"2018","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-554279","article-title":"Treatment of chronic graft-versus-host disease with bortezomib","volume":"124","author":"Pai","year":"2014","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"S233","DOI":"10.1016\/j.bbmt.2018.12.224","article-title":"Carfilzomib for Treatment of Refractory Chronic Gvhd: A Chronic GVHD Consortium Pilot Trial","volume":"25","author":"Pidala","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137641","article-title":"Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice","volume":"10","author":"Schutt","year":"2015","journal-title":"PloS One"},{"key":"B54","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00741.x","article-title":"Bruton\u2019s tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain","volume":"228","author":"Mohamed","year":"2009","journal-title":"Immunol Rev"},{"key":"B55","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41419-019-1413-8","article-title":"Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors","volume":"10","author":"Yang","year":"2019","journal-title":"Cell Death Dis"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1515\/bmc.2011.020","article-title":"Structure and function of Tec family kinase Itk","volume":"2","author":"Qi","year":"2011","journal-title":"Biomol Concepts"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.6.3737","article-title":"Syk is required for monocyte\/macrophage chemotaxis to CX3CL1 (Fractalkine)","volume":"175","author":"Gevrey","year":"2005","journal-title":"J Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2011.08072.x","article-title":"Tec family kinases Itk and Rlk\u200a\/\u200aTxk in T lymphocytes: cross-regulation of cytokine production and T-cell fates","volume":"278","author":"Gomez-Rodriguez","year":"2011","journal-title":"FEBS J"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500117","article-title":"Cytokines in Graft-versus-Host Disease","volume":"194","author":"Henden","year":"2015","journal-title":"J Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00751.x","article-title":"Abl tyrosine kinases in T-cell signaling","volume":"228","author":"Gu","year":"2009","journal-title":"Immunol Rev"},{"key":"B61","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.174","article-title":"Inhibition of EGFR Tyrosine Kinase by Erlotinib Prevents Sclerodermatous Graft-Versus-Host Disease in a Mouse Model","volume":"135","author":"Morin","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.drup.2012.01.005","article-title":"Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance","volume":"15","author":"Shukla","year":"2012","journal-title":"Drug Resist Update"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0694","article-title":"hOCT 1 and resistance to imatinib","volume":"106","author":"Crossman","year":"2005","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21406","article-title":"The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia","volume":"8","author":"Galimberti","year":"2017","journal-title":"Oncotarget"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000501061","article-title":"Treatment Selection for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors","volume":"64","author":"Ma","year":"2019","journal-title":"Chemotherapy"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.685650","article-title":"Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders","volume":"21","author":"Robak","year":"2012","journal-title":"Expert Opin Invest Drugs"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00603","article-title":"Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety","volume":"9","author":"Garc\u00eda-Guti\u00e9rrez","year":"2019","journal-title":"Front Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/art.24186","article-title":"Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis","volume":"60","author":"Akhmetshina","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-011110-130246","article-title":"Pathogenesis of liver fibrosis","volume":"6","author":"Hernandez-Gea","year":"2011","journal-title":"Annu Rev Pathol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1965","article-title":"Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib\u2013Findings from an Investigator-Initiated Phase II Study","volume":"22","author":"Niemann","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.122430","article-title":"SYK inhibitor entospletinib prevents ocular and skin GVHD in mice","volume":"3","author":"Poe","year":"2018","journal-title":"JCI Insight"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.212","article-title":"Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey","volume":"29","author":"Zeiser","year":"2015","journal-title":"Leukemia"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25376","article-title":"Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results","volume":"94","author":"Gonz\u00e1lez Vicent","year":"2019","journal-title":"Am J Hematol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167997","article-title":"Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease","volume":"11","author":"Belle","year":"2016","journal-title":"PloS One"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.4490.4490","article-title":"Novel Anti-Fibrotic Therapies for Experimental Chronic Graft-Versus-Host Disease","volume":"114","author":"Spriewald","year":"2009","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-204156","article-title":"Imatinib for refractory chronic graft-versus-host disease with fibrotic features","volume":"114","author":"Olivieri","year":"2009","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.03.006","article-title":"Imatinib mesylate for the treatment of steroid-refractory sclerotic-type cutaneous chronic graft-versus-host disease","volume":"21","author":"Baird","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-494278","article-title":"Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD","volume":"122","author":"Olivieri","year":"2013","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2012.07.017","article-title":"Combined inhibition of c-Abl and PDGF receptors for prevention and treatment of murine sclerodermatous chronic graft-versus-host disease","volume":"181","author":"Zerr","year":"2012","journal-title":"Am J Pathol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.4068\/cmj.2017.53.2.118","article-title":"Ameliorative Effects of Nilotinib on CCl4 Induced Liver Fibrosis Via Attenuation of RAGE\/HMGB1 Gene Expression and Oxidative Stress in Rat","volume":"53","author":"Khanjarsim","year":"2017","journal-title":"Chonnam Med J"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.10.021","article-title":"Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease","volume":"24","author":"Chen","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2016.12.002","article-title":"Ixazomib suppresses human dendritic cell and modulates murine graft-versus-host disease in a schedule-dependent fashion","volume":"48","author":"Al-Homsi","year":"2017","journal-title":"Exp Hematol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0123-z","article-title":"Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease","volume":"32","author":"Choi","year":"2018","journal-title":"Leukemia"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113915","article-title":"Hedgehog Pathway Inhibitor for Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD)","volume":"132","author":"Gupta","year":"2018","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-403428","article-title":"Inhibition of hedgehog signaling for the treatment of murine sclerodermatous chronic graft-versus-host disease","volume":"120","author":"Zerr","year":"2012","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017011239","article-title":"Phase 1 study of the Hedgehog pathway inhibitor sonidegib for steroid-refractory chronic graft-versus-host disease","volume":"1","author":"DeFilipp","year":"2017","journal-title":"Blood Adv"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc051946","article-title":"Imatinib for the treatment of pulmonary arterial hypertension","volume":"353","author":"Ghofrani","year":"2005","journal-title":"N Engl J Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2004.03.006","article-title":"Regulation of PDGF and its receptors in fibrotic diseases","volume":"15","author":"Bonner","year":"2004","journal-title":"Cytokine Growth Factor Rev"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/art.22314","article-title":"Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis","volume":"56","author":"Distler","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200404-531OC","article-title":"Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice","volume":"171","author":"Aono","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2013.11.017","article-title":"Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs","volume":"274","author":"Westra","year":"2014","journal-title":"Toxicol Appl Pharmacol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00300","article-title":"New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials","volume":"6","author":"Qu","year":"2015","journal-title":"Front Pharmacol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104866","article-title":"The CoV-2 outbreak: how hematologists could help to fight Covid-19","volume":"157","author":"Galimberti","year":"2020","journal-title":"Pharmacol Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.1.381","article-title":"Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis","volume":"99","author":"Beham-Schmid","year":"2002","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20380","article-title":"Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia","volume":"101","author":"Bueso-Ramos","year":"2004","journal-title":"Cancer"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1002\/art.24221","article-title":"Molecular framework for response to imatinib mesylate in systemic sclerosis","volume":"60","author":"Chung","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.252","article-title":"Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD","volume":"42","author":"Magro","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-204750","article-title":"Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease","volume":"114","author":"Magro","year":"2009","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.10","article-title":"Imatinib is effective for prevention and improvement of fibrotic fasciitis as a manifestation of chronic GVHD","volume":"47","author":"Osumi","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3271-3","article-title":"Association of the hOCT1\/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia","volume":"79","author":"Galeotti","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.08.021","article-title":"Notch Signaling Activity Determines Uptake and Biological Effect of Imatinib in Systemic Sclerosis Dermal Fibroblasts","volume":"139","author":"Harrach","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.2174\/15680266113139990094","article-title":"Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis","volume":"13","author":"Gomez-Puerta","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"B106","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","article-title":"Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment","volume":"8","author":"Du","year":"2017","journal-title":"Auto Immun Highlights"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0159","article-title":"Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)","volume":"100","author":"Lundin","year":"2002","journal-title":"Blood"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.324","article-title":"Alefacept treatment for refractory chronic extensive GVHD","volume":"43","author":"Shapira","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.10.039","article-title":"Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study","volume":"24","author":"Marinelli Busilacchi","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B110","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-020-0902-9","article-title":"Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria)","volume-title":"Bone Marrow Transplant","author":"Olivieri","year":"2020"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-020-02448-y","article-title":"FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host disease","volume":"29","author":"King-Kallimanis","year":"2020","journal-title":"Qual Life Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-595470","article-title":"Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease","volume":"125","author":"Flynn","year":"2015","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of therapeutic JAK 1\/2 blockade in graft-versus-host disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-114971","article-title":"Ruxolitinib and Steroid Refractory\/Dependent Bronchiolitis Obliterans after Hematopoietic Cell Transplantation: A Steroid Sparing Agent That Also Resulted in Improved Lung Function in Children","volume":"132","author":"Schoettler","year":"2018","journal-title":"Blood"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1738214","article-title":"Ruxolitinib for treatment of steroid-refractory graft-versus-host disease in adults: a systematic review and meta-analysis","volume":"13","author":"Hui","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"B116","doi-asserted-by":"crossref","DOI":"10.1007\/s12016-020-08786-6","article-title":"JAK Inhibitors: Prospects in Connective Tissue Diseases","volume-title":"Clinic Rev Allerg Immunol","author":"You","year":"2020"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001043","article-title":"A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease","volume":"4","author":"Schroeder","year":"2020","journal-title":"Blood Adv"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.06.040","article-title":"A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease","volume":"20","author":"Herrera","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0134-4","article-title":"Bortezomib is safe in and stabilizes pulmonary function in patients with allo-HSCT-associated pulmonary CGVHD","volume":"53","author":"Jain","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-017-0504-7","article-title":"Ixazomib: A Review in Relapsed and\/or Refractory Multiple Myeloma","volume":"12","author":"Al-Salama","year":"2017","journal-title":"Target Oncol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.bbmt.2018.12.099","article-title":"Ixazomib for Treatment of Refractory Chronic Graft Vs. Host Disease: A Chronic Gvhd Consortium Phase II Trial","volume":"25","author":"Pidala","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.213","article-title":"A Phase I\/2 Study of Ixazomib for Chronic Graft-Versus-Host Disease (cGVHD) Prophylaxis after Allogeneic Transplantation (alloHCT)","volume":"25","author":"Chhabra","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-780239","article-title":"Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease","volume":"131","author":"Nahas","year":"2018","journal-title":"Blood"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2008.05.011","article-title":"Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies","volume":"20","author":"Taylor","year":"2008","journal-title":"Curr Opin Immunol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202645","article-title":"Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy","volume":"190","author":"Bologna","year":"2013","journal-title":"J Immunol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.04.003","article-title":"Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis","volume":"15","author":"Kharfan-Dabaja","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-495895","article-title":"Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial","volume":"122","author":"Cutler","year":"2013","journal-title":"Blood"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0233","article-title":"Rituximab for steroid-refractory chronic graft-versus-host disease","volume":"108","author":"Cutler","year":"2006","journal-title":"Blood"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0158-9","article-title":"Prospective evaluation of sequential treatment of sclerotic chronic graft versus host disease with rituximab and nilotinib","volume":"53","author":"van der Wagen","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-307819","article-title":"Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease","volume":"117","author":"Sarantopoulos","year":"2011","journal-title":"Blood"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-017-0783-2","article-title":"Protective Effect of Rituximab in Chronic Graft-Versus-Host Disease Occurrence in Allogeneic Transplant patients with Epstein Barr Virus Viremia","volume":"33","author":"Ji","year":"2017","journal-title":"Indian J Hematol Blood Transfus"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0399-7","article-title":"Safety and efficacy of rituximab-based first line treatment of chronic GVHD","volume":"54","author":"Solomon","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0275","article-title":"The use of ofatumumab in the treatment of B-cell malignancies","volume":"13","author":"Soe","year":"2017","journal-title":"Future Oncol"},{"key":"B134","article-title":"Ofatumumab in a chronic lymphocytic leukemia patient with graft versus host disease and relapse after mini-allo BMT","volume":"20","author":"Urian","year":"2015","journal-title":"J BUON"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.03.014","article-title":"Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results","volume":"21","author":"Pidala","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.671.671","article-title":"Treatment of Patients with Steroid Refractory Acute Graft Vs Host Disease (SR-GvHD): A Matched Paired Analysis of Anti-CD26 (Begelomab) Compared to Other Treatment","volume":"128","author":"Bacigalupo","year":"2016","journal-title":"Blood"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402785","article-title":"Regulation of pulmonary graft-versus-host disease by IL-26+CD26+CD4 T lymphocytes","volume":"194","author":"Ohnuma","year":"2015","journal-title":"J Immunol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2012.01756.x","article-title":"Infliximab for steroid refractory or dependent gastrointestinal acute graft-versus-host disease in children after allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Yang","year":"2012","journal-title":"Pediatr Transplant"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.91","article-title":"Successful response to infliximab of recurrent pericardial graft versus host disease in a pediatric patient","volume":"48","author":"Rubio","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B140","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/ajh.20752","article-title":"Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation","volume":"82","author":"Busca","year":"2007","journal-title":"Am J Hematol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00056","article-title":"Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis","volume":"11","author":"Akg\u00fcn","year":"2020","journal-title":"Front Immunol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2009.03115.x","article-title":"Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model","volume":"128","author":"Hu","year":"2009","journal-title":"Immunology"},{"key":"B143","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.bbmt.2007.09.013","article-title":"Alemtuzumab-induced resolution of refractory cutaneous chronic graft-versus-host disease","volume":"14","author":"Ruiz-Arg\u00fcelles","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.02.007","article-title":"Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts","volume":"23","author":"Green","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-327536","article-title":"Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia","volume":"118","author":"Marsh","year":"2011","journal-title":"Blood"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0705-5","article-title":"Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.05.012","article-title":"Phase I Trial of Brentuximab Vedotin for Steroid-Refractory Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation","volume":"24","author":"DeFilipp","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1172\/JCI75935","article-title":"CSF-1-dependant donor-derived macrophages mediate chronic graft-versus-host disease","volume":"124","author":"Alexander","year":"2014","journal-title":"J Clin Invest"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1084\/jem.178.1.211","article-title":"Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses","volume":"178","author":"Miller","year":"1993","journal-title":"J Exp Med"},{"key":"B151","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.152.6.2753","article-title":"Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure\/function analysis in vitro and in human CD2 transgenic mice","volume":"152","author":"Majeau","year":"1994","journal-title":"J Immunol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.6.13.2327","article-title":"Alefacept: an expert review concerning the treatment of psoriasis","volume":"6","author":"Langley","year":"2005","journal-title":"Expert Opin Pharmacother"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14513","article-title":"A critical role for donor-derived IL-22 in cutaneous chronic GVHD","volume":"18","author":"Gartlan","year":"2018","journal-title":"Am J Transplant"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.92111","article-title":"An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition","volume":"2","author":"Forcade","year":"2017","journal-title":"JCI Insight"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-711796","article-title":"IL-2, the next best thing in chronic GVHD therapy","volume":"128","author":"Curtis","year":"2016","journal-title":"Blood"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-031210-101400","article-title":"Follicular helper CD4 T cells (TFH)","volume":"29","author":"Crotty","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"16636","DOI":"10.1038\/s41598-018-35109-9","article-title":"ROCK2, but not ROCK1 interacts with phosphorylated STAT3 and co-occupies TH17\/TFH gene promoters in TH17-activated human T cells","volume":"8","author":"Chen","year":"2018","journal-title":"Sci Rep"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-111896","article-title":"KD025-208: A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) \u2014 Pharmacodynamics and Updated Results","volume":"132","author":"Jagasia","year":"2018","journal-title":"Blood"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1605341","article-title":"Anti-IL-22 Antibody Attenuates Acute Graft-versus-Host Disease via Increasing Foxp3+ T Cell through Modulation of CD11b+ Cell Function","volume":"2018","author":"Wu","year":"2018","journal-title":"J Immunol Res"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1159\/000323011","article-title":"Simultaneous blockade of costimulatory signals CD28-CD80 and CD40-CD154 combined with monoclonal antibody against CD25 induced a stable chimerism and tolerance without graft-versus-host disease in rat","volume":"46","author":"Zhu","year":"2011","journal-title":"Eur Surg Res"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01206-10","article-title":"Sirtuin-1 targeting promotes Foxp3+ T-regulatory cell function and prolongs allograft survival","volume":"31","author":"Beier","year":"2011","journal-title":"Mol Cell Biol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2014.10","article-title":"Targeting sirtuin-1 alleviates experimental autoimmune colitis by induction of Foxp3+ T-regulatory cells","volume":"7","author":"Akimova","year":"2014","journal-title":"Mucosal Immunol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20132378","article-title":"SIRT1 deacetylates ROR\u03b3t and enhances Th17 cell generation","volume":"212","author":"Lim","year":"2015","journal-title":"J Exp Med"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1172\/JCI38902","article-title":"The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice","volume":"119","author":"Zhang","year":"2009","journal-title":"J Clin Invest"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-863233","article-title":"Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice","volume":"133","author":"Daenthanasanmak","year":"2019","journal-title":"Blood"},{"key":"B166","doi-asserted-by":"crossref","DOI":"10.1242\/dev.127.12.2763","article-title":"Hedgehog signals regulate multiple aspects of gastrointestinal development","volume":"127","author":"Ramalho-Santos","year":"2000","journal-title":"Development"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-014-1433-1","article-title":"The Hedgehog pathway: role in cell differentiation, polarity and proliferation","volume":"89","author":"Jia","year":"2015","journal-title":"Arch Toxicol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-841155","article-title":"Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice","volume":"132","author":"Radojcic","year":"2018","journal-title":"Blood"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-476218","article-title":"MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner","volume":"121","author":"Shindo","year":"2013","journal-title":"Blood"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.86331","article-title":"The MEK inhibitor trametinib separates murine graft-versus-host disease from graft-versus-tumor effects","volume":"1","author":"Itamura","year":"2016","journal-title":"JCI Insight"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-464198","article-title":"Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease","volume":"121","author":"Inamoto","year":"2013","journal-title":"Blood"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.3325\/cmj.2016.57.229","article-title":"High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-vs-host disease","volume":"57","author":"\u010ceovi\u0107","year":"2016","journal-title":"Croat Med J"},{"key":"B173","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-016-0343-5","article-title":"Targeting of PI3K\/AKT\/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development","volume":"9","author":"Herrero-S\u00e1nchez","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B174","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1146\/annurev-immunol-032712-095946","article-title":"Signaling by the phosphoinositide 3-kinase family in immune cells","volume":"31","author":"Okkenhaug","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15305","article-title":"Targeting PI3K\u03b4 function for amelioration of murine chronic graft-versus-host disease","volume":"19","author":"Paz","year":"2019","journal-title":"Am J Transplant"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-91439-8_12","article-title":"Idelalisib","volume":"212","author":"Zirlik","year":"2018","journal-title":"Recent Results Cancer Res"},{"key":"B177","article-title":"Safety and Efficacy of Idelalisib Treatment of Chronic Lymphocytic Leukemia (CLL) or Lymphoma Relapsing after Allogeneic Hematopoietic Cell Transplantation (alloHCT): A Survey By the EBMT Chronic Malignancies and Lymphoma Working Parties","volume":"130","author":"Dreger","year":"2017","journal-title":"Blood"},{"key":"B178","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jbior.2012.08.001","article-title":"Inositol 1,4,5-trisphosphate 3-kinase B (Itpkb) controls survival, proliferation and cytokine production in mouse peripheral T cells","volume":"53","author":"Pouillon","year":"2013","journal-title":"Adv Biol Regul"},{"key":"B179","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood.2019000032","article-title":"Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease","volume":"135","author":"Thangavelu","year":"2020","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.578314\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T12:11:54Z","timestamp":1696853514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.578314\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,9]]},"references-count":179,"alternative-id":["10.3389\/fimmu.2020.578314"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.578314","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,9]]},"article-number":"578314"}}